Drugs / YL217
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06859762 | Jul 2025 → Jul 2027 expected | neoplasm | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YL217 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06859762 ↗ |
| Modality | Other / unclassified | “YL217 is an antibody-drug conjugate (ADC)” NCT06859762 ↗ |
| Route | Intravenous | “Patients will be treated with YL217 intravenous(IV)infusion.” NCT06859762 ↗ |
| Target | CDH17 | “targets CDH17 (Cadherin-17) protein” NCT06859762 ↗ |